Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma

Mutationsin epidermal growth factor receptor (EGFR) are found in approximately 48% of Asian and 19% of Western patients with lung adenocarcinoma (LUAD), leading to aggressive tumor growth. While tyrosine kinase inhibitors (TKIs) like gefitinib and osimertinib target this mutation, treatments often f...

Full description

Bibliographic Details
Main Authors: Hippolyte Darré, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, Claire Couty, Bastien Martin, Evgueni Jacob, Michaël Duruisseaux, Jean-Louis Palgen, Claudio Monteiro, Adèle L’Hostis
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Biomedicines
Subjects:
lung adenocarcinoma
EGFR-TKI
precision oncology
in silico
computational oncology
Online Access:https://www.mdpi.com/2227-9059/12/3/704

Internet

https://www.mdpi.com/2227-9059/12/3/704

Similar Items